In recent months, innovation-driven pharmaceutical indices have surged collectively, with the Hang Seng Stock Connect China Innovation Pharma Index standing out by delivering a year-to-date return exceeding 60%. This remarkable performance has captured investor attention and spotlighted the rising momentum of China’s innovation drug sector. With increasing overseas acquisitions of Chinese-developed drugs, the industry is now widely recognized as one of China’s emerging strategic advantage sectors.
On June 30, the Hang Seng Stock Connect China Innovation Pharma Index announced a significant revision to its composition methodology—specifically, the removal of all CXO (Contract X Organization) companies. This move marks a pivotal moment: it is now the first index tracked by ETFs to explicitly exclude CXO firms and focus solely on core innovation drug enterprises. As a result, the index achieves what analysts are calling “100% purity” in representing true innovation-driven pharmaceutical companies.
👉 Discover how this refined index can sharpen your investment strategy in cutting-edge biotech.
What Are CXO Companies—and Why Exclude Them?
CXO organizations—including CROs (Contract Research Organizations), CMOs (Contract Manufacturing Organizations), and CDMOs (Contract Development and Manufacturing Organizations)—provide outsourced services across drug development, clinical trials, and manufacturing. While essential to the pharmaceutical ecosystem, these entities do not own core intellectual property (IP) for new drugs, do not bear R&D risks, and rarely participate in long-term revenue from drug commercialization or patent licensing.
This creates a fundamental divergence:
- Innovation drug companies generate value through proprietary R&D, global patent licensing, and commercial success.
- CXO companies earn stable service fees tied to project volume rather than product success.
By removing CXOs, the revised index eliminates indirect beneficiaries and focuses exclusively on firms whose business models revolve around drug discovery, IP ownership, and global partnership deals—offering a cleaner, more accurate reflection of the innovation drug ecosystem.
Impact of the Index Revision: Sharper Focus, Stronger Returns
Under the updated rules, five CXO firms will be removed from the index. These previously accounted for approximately 20% of total index weight, meaning their exclusion significantly reshapes the underlying portfolio.
Now, all constituents are pure-play innovation drug developers—many of which have established international partnerships through out-licensing agreements, a key indicator of global competitiveness.
Backtesting results following the exclusion of CXOs reveal compelling improvements:
- Since the index’s launch in 2023
- Throughout 2024
- And year-to-date in 2025
The adjusted index consistently outperforms its predecessor, delivering an annualized return above 30% with a higher Sharpe ratio, indicating superior risk-adjusted returns. This suggests that focusing on core innovators enhances both growth potential and portfolio efficiency.
Global Validation: Big Pharma Bets on Chinese Innovation
One of the strongest signals of China’s rising biotech prowess is the surge in cross-border licensing deals. In the first five months of 2025 alone, foreign pharmaceutical giants spent nearly as much on Chinese innovation drug patents as they did in all of 2024.
Why does this matter? Because multinational pharma companies are among the most sophisticated evaluators of drug potential. Their investments are based on rigorous scientific assessment, regulatory feasibility, and commercial outlook—not speculation.
Their growing appetite reflects two converging trends:
Supply-Side Strength
China’s innovation pipeline now ranks second globally, fueled by:
- Lower R&D costs
- High-speed clinical trial execution
- A deep talent pool in life sciences
- Advanced biologics and cell/gene therapy capabilities
Demand-Side Pressure
Meanwhile, Western pharmaceutical leaders face mounting challenges:
- Patent cliffs eroding blockbuster revenues
- Pricing pressures in mature markets
- Slower internal R&D pipelines
As a result, they increasingly look outward—turning to China as a strategic source of next-generation therapies.
This external validation has become a cornerstone for re-rating Chinese biotech stocks, reinforcing investor confidence in the sector’s long-term trajectory.
How Investors Can Access Pure Innovation Exposure
For retail investors, navigating individual stock selection in biotech can be risky due to high volatility and complex science. A more efficient approach? Exchange-Traded Funds (ETFs) that offer diversified exposure to leading innovators.
The Purest Play: Hang Seng Innovation Pharma ETF (159316)
Currently, this is the only ETF tracking the revised Hang Seng Stock Connect China Innovation Pharma Index, making it the sole vehicle offering 100% pure exposure to Hong Kong-listed innovation drug leaders. It provides seamless access to pioneers engaged in global out-licensing and cutting-edge R&D.
👉 Learn how you can position yourself at the forefront of this biotech revolution.
Broader Innovation Exposure: A-Shares & Cross-Market Options
Beyond Hong Kong, investors can consider:
- Innovation Pharma ETF (516080): Tracks A-share innovators like Hengrui Medicine and Fosun Pharma, covering the full innovation chain.
- Medicine ETF (512010): Offers broad exposure to A-share healthcare leaders across chemical pharma, medical devices, and services—with over RMB 20 billion in assets under management, it's the largest in its category.
- Stock Connect Healthcare ETF (513200): Targets top-tier healthcare firms within the Hong Kong Stock Connect universe.
These products allow investors to tailor their risk-return profiles—from focused innovation bets to diversified healthcare plays.
FAQs: Your Questions Answered
Q: What makes this index different from other innovation drug indices?
A: It’s the first ETF-tracked index to explicitly exclude CXO companies, ensuring 100% focus on firms that own drug IP and engage in global licensing—delivering unmatched purity in sector representation.
Q: Why are CXO companies excluded if they support drug development?
A: While CXOs play a vital role, their revenue model is service-based and decoupled from drug success. Including them dilutes exposure to true innovators who profit from patents and commercialization.
Q: Does excluding CXOs increase volatility?
A: Counterintuitively, no. Backtests show improved risk-adjusted returns post-revision, thanks to stronger alignment with high-growth innovators and reduced exposure to cyclical contract work.
Q: How often is the index rebalanced?
A: The index undergoes regular semi-annual reviews to ensure continued alignment with its methodology, maintaining relevance amid rapid industry changes.
Q: Can individual investors easily buy these ETFs?
A: Yes. Most are listed on major exchanges and accessible through standard brokerage accounts, offering low-cost, liquid access to premium innovation portfolios.
Q: Is now a good time to invest in innovation drugs?
A: With strong global demand, improving valuations, and accelerating deal flows, many analysts see favorable entry points—especially via pure-exposure vehicles like the updated index.
Looking Ahead: Beyond Single Therapies
While innovation drugs are leading today’s rally, broader healthcare segments—from digital health to precision medicine—are also showing signs of recovery. Regulatory support, post-pandemic healthcare spending rebound, and aging demographics create tailwinds across subsectors.
Yet within this landscape, innovation-driven biotech stands apart, backed by structural shifts rather than cyclical trends. As Chinese firms continue to break into global markets, indices like the purified Hang Seng benchmark offer investors a transparent, rules-based way to capture this transformation.
👉 See how aligning with high-potential sectors could redefine your investment outcomes.
Keywords: innovation drug ETF, Hang Seng Stock Connect China Innovation Pharma Index, CXO exclusion, pure innovation drug index, biotech investment, global licensing deals, pharmaceutical R&D, healthcare ETF